Phathom Pharmaceuticals

The FDA has approved Phathom Pharmaceuticals' Citizen Petition and will correct the Orange Book to recognize 10 years of New Chemical Entity exclusivity for VOQUEZNA (vonoprazan) tablets, extending through May 3, 2032.

• Phathom Pharmaceuticals' VOQUEZNA generated $55.3 million in net revenue during 2024, with Q4 sales reaching $29.7 million, marking an 81% increase from Q3. • The drug's market penetration expanded significantly with over 300,000 filled prescriptions to date and more than 20,000 healthcare providers prescribing the medication, demonstrating strong adoption in both gastroenterology and primary care settings. • Phathom is advancing VOQUEZNA's development program, including a planned Phase 2 trial for eosinophilic esophagitis (EoE) starting in Q2 2025, while maintaining broad commercial coverage reaching over 80% of U.S. commercial lives.

• Phathom Pharmaceuticals receives FDA approval for two vonoprazan-based combination therapies - Voquezna Triple Pak and Voquezna Dual Pak - for treating H. pylori infections. • Clinical trials demonstrated superior efficacy of vonoprazan-based treatments, particularly in clarithromycin-resistant infections, with eradication rates up to 84.7% compared to 78.8% for standard therapy. • The company secures $260 million in non-dilutive financing to support product launches and continued development, with $100 million available immediately and $160 million tied to potential erosive esophagitis approval.

• Phathom Pharmaceuticals presented data at ACG 2024 highlighting VOQUEZNA's efficacy for Non-Erosive GERD, including on-demand use and nocturnal symptom relief. • A post-hoc analysis of the PHALCON-NERD-201 trial showed that as-needed VOQUEZNA effectively relieved episodic heartburn in Non-Erosive GERD patients. • Data from a nocturnal GERD study demonstrated VOQUEZNA's ability to significantly improve heartburn-free nights and reduce nocturnal GERD symptom severity. • VOQUEZNA, a potassium-competitive acid blocker, is FDA-approved for various GERD treatments and H. pylori eradication.

• Phathom Pharmaceuticals presented data on VOQUEZNA® (vonoprazan) at the ACG 2024 meeting, highlighting its efficacy in treating GERD. • A post-hoc analysis of the PHALCON-NERD-201 trial showed that on-demand VOQUEZNA provided rapid relief of heartburn in Non-Erosive GERD patients. • Data from another study indicated VOQUEZNA significantly improved nocturnal GERD symptoms, offering better sleep quality for patients. • These findings support VOQUEZNA's potential as a versatile treatment option for both daytime and nighttime GERD symptoms.

• Phathom Pharmaceuticals presented data on VOQUEZNA® (vonoprazan) at the ACG 2024 meeting, highlighting its efficacy in treating GERD. • A post-hoc analysis of the PHALCON-NERD-201 trial showed that on-demand VOQUEZNA provided rapid relief of heartburn in Non-Erosive GERD patients. • Data from another study indicated that VOQUEZNA significantly improved nocturnal GERD symptoms, offering better sleep quality for patients. • These findings support VOQUEZNA's potential as a versatile treatment option for both daytime and nighttime GERD symptoms.

• The FDA has approved Voquezna (vonoprazan) 10 mg tablets for heartburn relief associated with Non-Erosive GERD in adults, marking a new option for millions. • Voquezna demonstrated a significant reduction in heartburn episodes in a Phase 3 trial, offering more 24-hour heartburn-free days compared to placebo. • The approval is based on the PHALCON-NERD-301 study, which showed Voquezna's efficacy and safety over a four-week treatment period. • Voquezna, a potassium-competitive acid blocker (PCAB), is now available by prescription and represents a novel approach to acid suppression therapy.